Who is eligible for clinical trial NCT05967416?

Participants must meet protocol criteria for Refractory Non-Hodgkin Lymphoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05967416 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2024-12-17

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05967416)

Phase 1 Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by IT- Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: SIRPant Immunotherapeutics, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

Who can join: Review the eligibility criteria below.

Location: City of Hope — Duarte, California

Age range: 18 Years

🧪 Interventions in This Study

SIRPant-M (BIOLOGICAL)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (3 Sites)

City of Hope — Duarte, California
Hackensack University Medical Center — Hackensack, New Jersey
MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (206) 909-1125

Email: jkijlstra@bobcatbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Refractory Non-Hodgkin Lymphoma

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). — Miami, Florida
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — San Francisco, California

Explore by condition: All Refractory Non-Hodgkin Lymphoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗